12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Company News  |  Deals

NeuroSearch, Teva deal

NeuroSearch sold Teva rights to Huntington's disease compound Huntexil pridopidine for DKK150 million ($26.1 million) up front, plus a potential DKK55 million ($9.6 million) in regulatory and commercial milestones. Teva said it believes Huntexil "holds promise for symptomatic relief of HD and merits additional study in late-stage clinical development." The company plans to conduct new clinical trials. In 2010, a meta-analysis of the Phase II HART and...

Read the full 324 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >